Cargando…

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation

Object: The treatment of choice in glioblastoma (GBM) is the maximal surgical extent of resection (EOR) followed by adjuvant chemo-radiotherapy. Furthermore, methylguanine-DNA methyltransferase (MGMT) promoter methylation is associated with prolonged overall survival (OS) and progression free surviv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchi, Francesco, Sahnane, Nora, Cerutti, Roberta, Cipriani, Debora, Barizzi, Jessica, Stefanini, Federico Mattia, Epistolio, Samantha, Cerati, Michele, Balbi, Sergio, Mazzucchelli, Luca, Sessa, Fausto, Pesce, Gianfranco Angelo, Reinert, Michael, Frattini, Milo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992596/ https://www.ncbi.nlm.nih.gov/pubmed/32039032 http://dx.doi.org/10.3389/fonc.2019.01569

Ejemplares similares

Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity
por: Cardia, Andrea, et al.
Publicado: (2023)

Functional and clinical significance of ROR1 in lung adenocarcinoma
por: Giovanna, Schiavone, et al.
Publicado: (2020)

Correction to: Functional and clinical significance of ROR1 in lung adenocarcinoma
por: Schiavone, Giovanna, et al.
Publicado: (2020)

Overview of recent advances in molecular analysis for diagnosing early stage lung cancer nodules
por: Frattini, Milo, et al.
Publicado: (2021)

Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer
por: Dazio, Giulia, et al.
Publicado: (2022)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
por: Yang, Pei, et al.
Publicado: (2015)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy
por: Cefalì, Marco, et al.
Publicado: (2022)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

A Pilot, Prospective, Observational Study to Investigate the Value of NGS in Liquid Biopsies to Predict Tumor Response After Neoadjuvant Chemo-Radiotherapy in Patients With Locally Advanced Rectal Cancer: The LiBReCa Study
por: Roesel, Raffaello, et al.
Publicado: (2022)

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma
por: Hareedy, Amal Ahmed, et al.
Publicado: (2022)

Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3
por: Forcella, Matilde, et al.
Publicado: (2017)

Role of NEU3 Overexpression in the Prediction of Efficacy of EGFR-Targeted Therapies in Colon Cancer Cell Lines
por: Bovio, Federica, et al.
Publicado: (2020)

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
por: Cekani, Elona, et al.
Publicado: (2022)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
por: Combs, Stephanie E, et al.
Publicado: (2011)

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma
por: Schiffgens, Salveena, et al.
Publicado: (2016)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status
por: Wang, Ke, et al.
Publicado: (2021)

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
por: Molinari, F, et al.
Publicado: (2009)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies
por: Jensen, Steffen Grann, et al.
Publicado: (2021)

MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion
por: Fontana, Laura, et al.
Publicado: (2016)

Immune-Related lncRNA Risk Signatures Predict Survival of IDH Wild-Type and MGMT Promoter Unmethylated Glioblastoma
por: Li, Xiaozhi, et al.
Publicado: (2020)

MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [(18)F]FDOPA Uptake in Primary Brain Tumors
por: Cimini, Andrea, et al.
Publicado: (2020)

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma
por: Pandith, Arshad A, et al.
Publicado: (2020)

Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI
por: Sha, Yongjian, et al.
Publicado: (2023)

A qPCR technology for direct quantification of methylation in untreated DNA
por: Bendixen, Kamilla Kolding, et al.
Publicado: (2023)

The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis
por: Zhou, Min, et al.
Publicado: (2019)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents
por: Kurdi, Maher, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

P1245 Polymorphic Variants of HSD3B1 Gene Confer Different Outcome in Specific Subgroups of Patients Infected With SARS-CoV-2
por: Epistolio, Samantha, et al.
Publicado: (2022)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vcrmbtjk2rfuf472uk3c3albg5